Schedule 13G ownership disclosure

Spyre Therapeutics Inc

Security class unavailable · CUSIP: 00773J202

Event date: 2023-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
653,409
Percent of class
1.8100%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001999371-24-002149
Form type
SC 13G/A
Filer
Affinity Asset Advisors, LLC
CIK
CIK 1773195
Filed
Feb 13, 2024
Reporting period
Dec 31, 2023
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub